Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma Clinical Trial

Official title:

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Universal BCMA-targeted LUCAR-B68 Cells Product in Patients With Relapsed/Refractory Multiple Myeloma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05498545
• Other study ID #: BM2L202201
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: September 2022
• Est. completion date: March 2027

Study information

• Verified date: August 2022
• Source: Second Affiliated Hospital of Xi'an Jiaotong University
• Contact: Wan-Hong Zhao, PhD
• Phone: 86-29-87679459
• Email: zhaowanhong68[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Universal BCMA-targeted LUCAR-B68 Cells Product in Patients With Relapsed/Refractory Multiple Myeloma

Description:

This is a prospective, single-arm, open-label, dose-finding and dose-expansion study that evaluates the safety, tolerability, PK, and anti-tumor efficacy of LUCAR-B68 cell preparations in relapsed/refractory multiple myeloma subjects who received adequate standard therapy

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 34
• Est. completion date: March 2027
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The subject voluntarily participates in the clinical study; Fully understand and be Informed of the study and sign the Informed consent (Informed Consent Form, ICF); Willing to follow and able to complete all test procedures; Informed consent must be obtained before initiating any tests or procedures related to the study that are not part of the standard treatment of the subject's disease;

2. Subjects = 18 years of age.

3. Eastern Cooperative Oncology Group performance status score of 0, 1, or 2;

4. Documented initial diagnosis of MM according to IMWG diagnostic criteria.

5. Presence of measurable disease at screening.

6. Received a PI and an IMiD (except thalidomide).

7. Received at least 3 prior lines of therapy for multiple myeloma, undergone at least 1 complete cycle of treatment for each line, unless progressive disease (PD) was documented by IMWG criteria as the best response to the regimen. Also, subjects refractory or intolerant to any PI and any IMiD in their previous treatment afterwards are eligible.

8. Expected survival = 3 months.

9. Clinical laboratory values meet screening visit criteria

10. Fertile women must be negative using a highly sensitive serum pregnancy test (ß human chorionic gonadotropin [ß -HCG]) at screening time and before initial treatment with cyclophosphamide and fludarabine;

Exclusion Criteria:

1. No response to prior BCMA-targeted CAR-T therapy (except in subjects who relapsed after CR to prior CAR-T treatment);

2. Prior treatment with any antibody targeting BCMA;

3. Known active, or prior history of central nervous system (CNS) involvement, or clinical signs of membrane/spinal membrane involvement of multiple myeloma;

4. Serious underlying medical conditions

5. Positive of any hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), human immunodeficiency virus antibody (HIV-Ab) at the time of screening;

6. Male subjects who have a birth plan during the study period or within 1 year after the study treatment

7. Female subjects who are pregnant, breast-feeding, or plan to become pregnant during the study period or within 1 year after the study treatment

8. The investigator considered that the subjects were not suitable for any conditions of participation in the study

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Relapsed/Refractory Multiple Myeloma

Intervention

Biological:
• LUCAR-B68 cells product
Before treatment with LUCAR-B68 cells, subjects will receive a conditioning regimen

Locations

Country	Name	City	State
China	Second Affiliated Hospital of Xi'an Jiaotong University	Xi'an	Shaanxi

Sponsors (2)

Lead Sponsor	Collaborator
Second Affiliated Hospital of Xi'an Jiaotong University	Nanjing Legend Biotech Co.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence, severity, and type of treatment-emergent adverse events (TEAEs)	An adverse event refers to any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product (investigational or non-investigational), which does not necessarily have a causal relationship with the treatment	Minimum 2 years after LUCAR-B68 infusion (Day 1
Primary	Dose-limiting toxicity (DLT) rate	Dose-limiting toxicity (DLT) refers to a drug-related toxicity during treatment with the drug, the severity of which is clinically unacceptable, limiting the further escalation of drug dose	Minimum 2 years after LUCAR-B68 infusion (Day 1)
Primary	Recommended Phase 2 dose (RP2D) finding	RP2D established through ATD+BOIN design	30 days after LUCAR-B68 infusion (Day 1)
Primary	CAR positive NK cells in peripheral blood and bone marrow	CAR positive NK cells in peripheral blood and bone marrow after LUCAR-B68 infusion	Minimum 2 years after LUCAR-B68 infusion (Day 1)
Primary	CAR transgene levels in peripheral blood	CAR transgene levels in peripheral blood after LUCAR-B68 infusion	Minimum 2 years after LUCAR-B68 infusion (Day 1)
Secondary	Overall response rate (ORR)	The ORR is defined as the percentage of participants who achieve partial response (PR) or better according to international myeloma working group (IMWG) criteria	Minimum 2 years after LUCAR-B68 infusion (Day 1)
Secondary	Duration of Response (DOR)	Duration of response (DOR) will be calculated among responders (with a PR or better response) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG criteria or death due to any cause, whichever occurs first	Minimum 2 years after LUCAR-B68 infusion (Day 1)
Secondary	Time to Response (TTR)	Time to response (TTR) is defined as the time between date of the initial infusion of LCAR-B38M CAR-T cells and the first efficacy evaluation that the participant has met all criteria for PR or better	Minimum 2 years after LUCAR-B68 infusion (Day 1)
Secondary	Progress Free Survival (PFS)	Progression Free Survival (PFS) is defined as the time from the date of first infusion of the LUCAR-B68 to the first documented disease progression (according to IMWG criteria) or death (due to any cause), whichever occurs first	2 years after LUCAR-B68 infusion (Day 1)
Secondary	Overall Survival (OS)	Overall Survival (OS) is defined as the time from the date of first infusion of LUCAR-B68 to death of the subject	Minimum 2 years after LUCAR-B68 infusion (Day 1)
Secondary	Incidence of anti- LUCAR-B68 antibody	Venous blood samples will be collected to measure LUCAR-B68 positive cell concentrations and the transgenic level of LUCAR-B68, at the time points when anti- LUCAR-B68 antibody serum samples are evaluated	Minimum 2 years after LUCAR-B68 infusion (Day 1)